Complement Factor B (CFB) Deficiency is an exceptionally rare autosomal recessive primary immunodeficiency caused by loss-of-function mutations in the CFB gene on chromosome 6p21.33 within the major histocompatibility complex region, encoding the serine protease that serves as the catalytic subunit of the alternative pathway C3 convertase (C3bBb) — its absence completely abolishes the alternative pathway amplification loop, eliminating the spontaneous antibody-independent complement surveillance mechanism that continuously opsonizes and lyses encapsulated bacteria even before adaptive immunity has time to respond, leaving patients with fewer than 20 reported cases worldwide profoundly susceptible to invasive Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis infections that can progress to bacteremia, meningitis, and septic shock within hours; the care tech platforms supporting CFB deficiency management integrate AP50 and CH50 complement function laboratories, infectious disease alert dashboards, pneumococcal and Hib serotype surveillance registries, vaccination scheduling engines, prophylactic antibiotic dispensing systems, genetic counseling coordination portals, and specialist immunology teleconsultation services serving patients, families, immunologists, infectious disease physicians, and genetic counselors — and when any of these systems become unavailable, the fragile surveillance net that stands between an ultra-rare immunodeficient patient and life-threatening encapsulated bacterial sepsis develops critical gaps that no manual process can reliably close.
This guide covers the specific monitoring requirements for CFB deficiency care tech platforms in 2026, including alternative pathway complement function surveillance, encapsulated bacterial infection alerting, pneumococcal and Hib infection tracking, vaccination status coordination, prophylaxis adherence monitoring, genetic cascade screening, and chronic lung disease surveillance — along with Vigilmon alerting tiers, status page strategy, and a complete setup walkthrough tailored to the clinical urgency of this ultra-rare complement disorder.
Why Complement Factor B Deficiency Care Tech Platforms Cannot Afford Downtime
CFB deficiency management rests on four interconnected pillars: broader vaccine coverage than standard complement deficiency protocols (requiring pneumococcal conjugate and polysaccharide vaccines in addition to meningococcal and Hib series), continuous surveillance for encapsulated bacterial infections across multiple species, lifelong antibiotic prophylaxis with adherence monitoring, and genetic counseling including cascade family testing in a condition so rare that even specialist immunology centers may encounter only one or two cases in a career. When the platforms coordinating these pillars experience downtime, vaccination gaps go unrecognized, fever alerts fail to reach on-call teams, prophylaxis refill lapses are missed, and families awaiting genetic results are left without guidance — all against the backdrop of a condition where a missed pneumococcal bacteremia can kill within 24 hours.
CFB is the catalytic subunit of the alternative pathway C3 convertase — its absence eliminates the amplification loop that sustains complement activation against encapsulated bacteria. Under normal physiology, spontaneous hydrolysis of C3 produces C3(H₂O) that binds Factor B; Factor D then cleaves Factor B into Ba and Bb, generating the fluid-phase C3 convertase C3(H₂O)Bb that deposits C3b onto bacterial surfaces. Once C3b is surface-deposited, it recruits another molecule of Factor B which is again cleaved by Factor D, producing the stable surface-bound C3bBb convertase — the amplification loop that exponentially increases C3b deposition, opsonization density, and ultimately MAC (C5b-9) formation. CFB deficiency at any step in this pathway means C3bBb cannot form: C3b deposition remains at basal tickover levels without amplification, opsonophagocytic killing by neutrophils and macrophages is severely impaired because complement receptor CR1/CR3-mediated phagocytosis depends on dense surface C3b and iC3b coating, and the alternative pathway contribution to classical and lectin pathway amplification is also lost, meaning even antibody-mediated classical activation generates less downstream bactericidal activity than in immunocompetent individuals.
Unlike terminal complement deficiencies where Neisseria meningitidis predominates, CFB deficiency creates susceptibility to pneumococcal and H. influenzae infections through impaired alternative pathway opsonization. Terminal complement deficiencies (C5–C9, properdin, Factor D) primarily compromise MAC formation and are classically associated with recurrent Neisseria infections because Neisseria killing is uniquely MAC-dependent. CFB deficiency, by contrast, abolishes the upstream amplification loop — this impairs opsonization broadly, making encapsulated organisms like Streptococcus pneumoniae and Haemophilus influenzae type b, which rely heavily on complement-mediated opsonophagocytosis for clearance, the primary infecting pathogens. Pneumococcal bacteremia and Hib bacteremia dominate the clinical picture in reported CFB deficiency cases, with pneumococcal pneumonia, empyema, and meningitis representing the most life-threatening presentations. Neisseria susceptibility exists but is secondary; this distinction is critical for vaccination strategy because pneumococcal vaccine series must be prioritized and completed before meningococcal prophylaxis, and monitoring platforms must be configured to track pneumococcal and Hib infections with the same intensity as meningococcal alerts applied in terminal deficiency programs.
Complement Factor B Deficiency is among the rarest complement deficiencies, with fewer than 20 cases in the published literature, requiring specialized immunology expertise and comprehensive surveillance. The extreme rarity of CFB deficiency — rarer than Factor D or properdin deficiency, and vastly rarer than C2 or MBL deficiency — creates significant diagnostic delays because most clinicians, and many immunologists, will never encounter a case. Patients often accumulate years of recurrent pneumococcal and Hib infections before complement testing is ordered, and when complement panels are run, the finding of a near-zero AP50 with preserved CH50 can be misinterpreted without awareness that CFB deficiency specifically eliminates alternative pathway hemolytic activity while leaving the classical pathway structurally intact (though functionally suboptimal due to absent amplification). The autosomal recessive inheritance pattern means siblings have a one-in-four risk of being affected, parents are obligate heterozygous carriers, and consanguinity is overrepresented in reported cases. The potential for underdiagnosis is substantial: patients dying of overwhelming pneumococcal sepsis without prior immunological evaluation represent the dark figure of CFB deficiency epidemiology. Care tech platforms serving these patients must therefore support not only active patient management but also diagnostic pathway coordination and family cascade programs that extend the reach of a single identified proband into a broader at-risk family network.
What to Monitor on a Complement Factor B Deficiency Care Tech Platform
Alternative Pathway Complement Function Monitoring Platform (AP50/CH50)
The diagnostic and monitoring cornerstone of CFB deficiency management is the AP50 (alternative pathway hemolytic assay using rabbit or guinea pig erythrocytes in EGTA-Mg buffer that chelates calcium to block classical pathway), which should be near-zero or completely absent in CFB deficiency, reflecting the inability to form C3bBb convertase. CH50 (total classical pathway hemolytic assay) may be reduced below normal range because the alternative pathway amplification loop normally augments downstream complement activation triggered through the classical route — its absence results in submaximal C5b-9 generation even when IgG-coated erythrocytes are used as activators. The monitoring platform must track quantitative CFB antigen levels by ELISA or nephelometry, CFB functional hemolytic reconstitution assays (confirming deficiency is corrected by addition of purified Factor B), Factor D levels (occasionally co-deficient in MHC-linked complement mutations), properdin levels (to exclude combined AP deficiency), C3 levels (may be chronically low due to absent regulation of tickover — or normal depending on infection burden), C4 levels (to monitor classical pathway integrity), and periodic full complement panel reassessment every six to twelve months. Any uptime gap on the laboratory data integration endpoint means complement function trend data is invisible to the clinical team, risking missed deterioration or diagnostic confusion during intercurrent infections. Check at a 1-minute interval.
Encapsulated Bacterial Infection Surveillance and Sepsis Alert Dashboard
The infection surveillance dashboard for CFB deficiency must cover a broader bacterial target spectrum than meningococcal-focused terminal complement deficiency programs. Fever alerting should trigger at 38.0°C (lower threshold than standard, given that complement-deficient patients may mount blunted early inflammatory responses), with immediate escalation protocols for temperatures exceeding 38.5°C. Blood culture order confirmation and result integration must track Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis, and other encapsulated organisms including Klebsiella pneumoniae and Salmonella species. Pneumococcal urinary antigen testing results must be captured for rapid pneumococcal diagnosis. Hib bacteremia detection requires documentation of serotype confirmation. CSF culture results must trigger meningitis episode alerts. Serogroup and serotype identification for all encapsulated isolates must feed into the vaccination effectiveness module to differentiate vaccine serotype versus non-vaccine serotype breakthrough infections. Bacteremia alert escalation must page on-call immunology and infectious disease simultaneously. Septic shock early warning scoring (qSOFA, NEWS2) must be integrated for hospitalized patients. Monitor at a 1-minute interval with 24/7 coverage.
Pneumococcal Infection Monitoring Platform
Given that Streptococcus pneumoniae represents the dominant infecting pathogen in CFB deficiency, a dedicated pneumococcal surveillance module must document every pneumococcal bacteremia episode including date, clinical syndrome (bacteremia without focus, pneumococcal pneumonia, empyema, meningitis, peritonitis), pneumococcal serotype, penicillin susceptibility, cephalosporin susceptibility, and whether the serotype was covered by the patient's most recent PCV15, PCV20, or PPSV23 vaccination. Recurrent pneumococcal pneumonia episodes must be tracked with interval calculation to identify increasing frequency, a harbinger of prophylaxis failure or vaccination gap. Empyema surveillance with pleural fluid culture results must be integrated. Pneumococcal meningitis episodes require immediate escalation given their potential for catastrophic neurological sequelae. Penicillin-resistant and multidrug-resistant pneumococcal isolates must trigger urgent antimicrobial stewardship consultation alerts. The platform must support longitudinal serotype mapping to detect emergence of non-vaccine serotypes as the predominant clinical isolates, informing decisions about PPSV23 booster timing and expanded conjugate vaccine use. Check at a 1-minute interval.
Vaccination Status and Immunization Coordination Platform
The vaccination schedule for CFB deficiency is more complex than for terminal complement deficiencies because pneumococcal vaccine coverage must be comprehensive and systematically maintained. The platform must track PCV15 or PCV20 primary series completion with age-appropriate dosing schedules, PPSV23 booster administration including mandatory five-year revaccination (with alerting if the revaccination window is approaching or overdue), Hib conjugate vaccine completion for all age groups including adults who were not vaccinated in childhood, MenACWY primary series with three-to-five-year booster scheduling, MenB two-dose or three-dose series depending on product used, annual seasonal influenza vaccination with each season's administration recorded, and COVID-19 primary series plus updated booster documentation. Vaccination gap alerting must fire at 30 days before due date for boosters, not just when overdue. Breakthrough infections despite vaccination must automatically prompt a clinical review flag to consider whether serotype replacement has occurred. Family member vaccination cascade tracking is critical: unaffected siblings and parents who are obligate carriers do not require immunodeficiency vaccination schedules, but identified sibling cases do, and the platform must support family-unit vaccination views. Check at a 2-minute interval.
Antibiotic Prophylaxis Adherence Monitoring Platform
Lifelong prophylactic antibiotics are standard of care for CFB deficiency, as for other complement deficiencies associated with encapsulated bacterial susceptibility. The platform must document the prescribed prophylaxis regimen — typically penicillin VK 250 mg twice daily in children or 500 mg twice daily in adults, or amoxicillin 250–500 mg daily as an alternative — alongside penicillin allergy documentation and recorded alternatives (azithromycin 250 mg daily for penicillin-allergic patients, or cephalexin where cephalosporin cross-reactivity risk is deemed acceptable after allergy evaluation). Pharmacy electronic prescribing refill gap detection must alert the care coordinator when a prescription has not been refilled within five days of the expected refill date, as a proxy for adherence failure. Monthly adherence trend visualization must flag patients whose refill intervals suggest intermittent nonadherence. Side effect documentation — gastrointestinal intolerance, rash, Clostridioides difficile-associated diarrhea — must be captured to enable timely prophylaxis regimen switches. Decisions to discontinue prophylaxis (uncommon given infection history in CFB deficiency) require documented clinical rationale, and any discontinued prophylaxis must trigger heightened infection surveillance alerting. Check at a 2-minute interval.
Genetic Counseling and Family Cascade Screening Coordination Platform
Given the extreme rarity of CFB deficiency and its autosomal recessive inheritance, the genetic coordination platform carries unusual importance. The platform must document the specific CFB gene mutation(s) identified in the proband — homozygous versus compound heterozygous, variant classification (pathogenic, likely pathogenic, variant of uncertain significance), and the laboratory that performed sequencing. Heterozygous carrier testing results for both biological parents must be recorded, confirming autosomal recessive inheritance and enabling sibling risk counseling. Extended family cascade screening workflow management must support consanguineous families in whom multiple branches may carry the same pathogenic variant. Prenatal counseling session documentation and reproductive decision support materials must be accessible through the platform. Newborn sibling testing protocols — including timing of AP50 testing in neonates, which may be unreliable before three to six months of age due to physiological complement immaturity — must be coordinated with the genetic counseling team. Genetic counselor appointment scheduling, report delivery confirmation, and family variant registry maintenance must all generate uptime-dependent workflow dependencies. Check at a 2-minute interval.
Recurrent Sinopulmonary Infection and Chronic Lung Disease Monitoring Platform
Repeated episodes of pneumococcal pneumonia and Hib lower respiratory tract infection in CFB deficiency patients create cumulative pulmonary injury risk. The platform must track sinusitis episode frequency, etiology where microbiologically documented, and antibiotic treatment courses to identify patients with recurrent or chronic sinusitis warranting ENT evaluation. Otitis media surveillance is particularly relevant in pediatric patients, with documentation of middle ear effusions, tympanostomy tube placement, and audiological outcomes. Bronchiectasis development — the most significant long-term pulmonary complication of repeated bacterial pneumonias — must be monitored through pulmonary function testing results (FEV1, FVC, FEV1/FVC ratio trending over time) and chest CT bronchiectasis scoring using validated instruments such as the Reiff or Bhalla score. Patients with established bronchiectasis require airway clearance therapy adherence tracking, mucoactive agent prescription documentation, and respiratory physiotherapist contact records. Exacerbation frequency in bronchiectasis patients must be monitored as a quality metric for the program. Check at a 2-minute interval.
Telemedicine and Coordinator Platform
The telemedicine and care coordination platform enables immunologists, infectious disease specialists, and genetic counselors — concentrated in major academic centers — to deliver CFB deficiency expertise to patients who may live far from specialist facilities. The platform must maintain video consultation uptime, secure messaging between patients and coordinator teams, and appointment scheduling continuity. Given the extreme rarity of CFB deficiency, many patients may be managed by a single national or regional expert center via telemedicine, making platform availability directly equivalent to access to specialist care. Coordinator availability dashboards, urgent consultation escalation pathways, and after-hours emergency contact systems must be monitored continuously. Check at a 2-minute interval.
EHR Integration Endpoint
The EHR integration endpoint synchronizes complement function laboratory results, infection episode documentation, vaccination records, antibiotic prescriptions, and genetic counseling notes between the CFB deficiency care platform and the institutional electronic health record, ensuring that emergency department clinicians seeing a patient in septic shock have immediate access to the diagnosis, current prophylaxis regimen, vaccination history, and specialist contact details. Any downtime on this endpoint creates dangerous information silos at the moment of highest clinical need. Check at a 5-minute interval.
Authentication Service
The authentication service controls access to complement function data, genetic information, and infection surveillance dashboards for clinicians, patients, and families. Downtime on the authentication service locks all users out of the platform simultaneously, rendering every monitoring module inaccessible. Check at a 1-minute interval.
SSL Certificates Across All Platform Domains
All CFB deficiency care platform domains — complement laboratory portals, infection alert dashboards, vaccination scheduling systems, telemedicine endpoints, EHR integration APIs, and genetic counseling portals — must maintain valid SSL/TLS certificates with automated expiry alerting at 30, 14, and 7 days before expiration. Certificate failures produce browser security warnings that prevent patients and clinicians from accessing the platform, effectively creating a downtime event with no infrastructure cause.
Alerting Strategy for Complement Factor B Deficiency Care Tech Platforms
Effective alerting for CFB deficiency platforms requires four tiers calibrated to the clinical consequences of each system failure, reflecting both the extreme rarity of the condition and the potentially fatal speed of encapsulated bacterial infection progression.
Tier 1 — Immediate (0–2 minutes, 24/7 multi-channel): AP50/CH50 complement function monitoring platform, encapsulated bacterial infection surveillance and sepsis alert dashboard, pneumococcal infection monitoring platform, and the authentication service. These systems sit in the direct patient-safety pathway: a sepsis alert that cannot be delivered because the surveillance platform is down represents an immediate threat to life. Pages must reach on-call immunology, infectious disease, and the care coordinator simultaneously, via SMS, phone call, and push notification.
Tier 2 — Urgent (2–5 minutes, business hours primary / on-call after hours): Vaccination status and immunization coordination platform, antibiotic prophylaxis adherence monitoring platform, and the telemedicine and coordinator platform. Failures here create vaccination gaps and prophylaxis lapses that increase infection risk over days to weeks — urgent but not instantaneously life-threatening.
Tier 3 — High (5–15 minutes, business hours): Genetic counseling and family cascade screening coordination platform, recurrent sinopulmonary infection and chronic lung disease monitoring platform, and the EHR integration endpoint. Downtime in these systems disrupts the longer-arc management of CFB deficiency — bronchiectasis tracking, family screening workflows, and shared medical records — with consequences that compound over weeks.
Tier 4 — Standard (15–30 minutes, business hours): SSL certificate expiry alerts for non-critical subdomains, administrative reporting modules, and non-urgent analytics dashboards.
The extreme rarity of CFB deficiency means that the clinical team responsible for each patient may be a single immunologist managing the case nationwide. Alert routing must therefore be configured to reach backup on-call specialists when the primary clinician is unreachable, with escalation to department heads within 15 minutes for Tier 1 failures — a configuration Vigilmon supports through multi-step escalation chains and team rotation schedules.
Status Page as a Clinical Safety Signal
For CFB deficiency care programs, the platform status page serves a function beyond operational transparency: it is a real-time communication channel to patients and families who, because of the extreme rarity of their condition, have often invested significant personal effort in accessing the platform and have no equivalent alternative. When the vaccination scheduling system or telemedicine portal shows a degraded status, a patient in a remote location can make an informed decision to call the specialist directly rather than waiting for a portal that will not recover in time for their appointment. This proactive transparency is especially critical for CFB deficiency patients in whom a delayed vaccination booster or a missed antibiotic refill reminder represents a measurable increase in pneumococcal bacteremia risk.
The status page should display component-level status for each monitoring module — complement function laboratory integration, infection surveillance, pneumococcal monitoring, vaccination coordination, prophylaxis adherence, genetic counseling, lung disease monitoring, telemedicine, EHR, and authentication — with plain-language descriptions that non-technical patients and families can interpret. Incident postmortems must be published within 48 hours of resolution, documenting root cause, duration, and safeguards implemented to prevent recurrence, building the institutional trust that ultra-rare disease patient communities require before they will rely on digital health platforms as their primary care coordination infrastructure.
The Business Case: Encapsulated Bacterial Sepsis Prevention and CFB Deficiency Program Quality
The preventable mortality argument for uninterrupted CFB deficiency platform uptime is stark: overwhelming pneumococcal sepsis in a complement-deficient individual carries a mortality rate exceeding 50% without rapid diagnosis and treatment, and CFB deficiency patients who miss prophylactic antibiotic doses or fall behind on pneumococcal vaccine boosters face materially higher risk of a fatal infectious episode. The cost of a single pneumococcal bacteremia admission — ICU days, broad-spectrum antibiotics, potential neurological rehabilitation after meningitis — vastly exceeds the annual cost of a comprehensive monitoring platform, making the business case for investment in uptime monitoring one of the most straightforward in rare immunodeficiency care.
For specialist immunology centers managing CFB deficiency cohorts, platform reliability is inseparable from clinical program reputation. Because fewer than 20 CFB deficiency cases have been published worldwide, any center managing even two or three patients represents a meaningful fraction of the global clinical experience. Accreditation bodies for primary immunodeficiency programs — including ESID, IPOPI, and the Jeffrey Modell Foundation network — assess the robustness of infection surveillance, vaccination tracking, and genetic counseling coordination as quality markers. A documented uptime record with Vigilmon incident reports serves as objective evidence of program quality during accreditation reviews and grant applications.
The genetic counseling and family cascade dimension of CFB deficiency creates additional business value for platform reliability. Each identified proband has a 25% sibling risk and two obligate carrier parents. In consanguineous families, extended pedigree screening may identify additional affected or at-risk individuals. A functional cascade screening coordination platform converts each proband identification into a family-level intervention that may prevent multiple future cases of pneumococcal sepsis. Downtime on the genetic counseling module disrupts appointment pipelines, delays variant reporting to families, and slows the creation of the longitudinal family registry that enables the research publications that attract further CFB deficiency cases to the center — creating a virtuous cycle whose first dependency is platform uptime.
Vigilmon Setup for Complement Factor B Deficiency Care Tech Platforms
A practical starting configuration:
| Monitor | Type | Interval | Alert Tier | |---------|------|----------|------------| | AP50/CH50 Complement Function Platform | HTTPS | 1 min | Tier 1 | | Encapsulated Bacterial Sepsis Alert Dashboard | HTTPS | 1 min | Tier 1 | | Pneumococcal Infection Monitoring Platform | HTTPS | 1 min | Tier 1 | | Authentication Service | HTTPS | 1 min | Tier 1 | | Vaccination Status and Immunization Coordination | HTTPS | 2 min | Tier 2 | | Antibiotic Prophylaxis Adherence Monitor | HTTPS | 2 min | Tier 2 | | Telemedicine and Coordinator Platform | HTTPS | 2 min | Tier 2 | | Genetic Counseling and Family Cascade Platform | HTTPS | 2 min | Tier 3 | | Sinopulmonary and Chronic Lung Disease Monitor | HTTPS | 2 min | Tier 3 | | EHR Integration Endpoint | HTTPS | 5 min | Tier 3 | | SSL Certificates (all domains) | SSL | Daily | Tier 4 |
Getting started:
- Create a free account at vigilmon.online and configure a project named "CFB Deficiency Care Platform."
- Add the AP50/CH50 complement function monitoring platform URL as an HTTPS monitor with a 1-minute interval and keyword check for the complement panel dashboard load confirmation string.
- Add the encapsulated bacterial infection surveillance and sepsis alert dashboard with a 1-minute interval; configure a TCP port check on the alert delivery API endpoint in addition to the HTTPS check.
- Add the pneumococcal infection monitoring platform with a 1-minute interval and response time alerting threshold of 2 seconds, ensuring the pneumococcal serotype registry query endpoint is included.
- Add the authentication service with a 1-minute interval and configure a secondary monitor on the OAuth token endpoint to detect partial authentication failures that may not surface on the main login page.
- Add the vaccination status and immunization coordination platform with a 2-minute interval; configure a keyword check confirming that the patient vaccination schedule view loads correctly.
- Add the antibiotic prophylaxis adherence monitoring platform with a 2-minute interval; include the pharmacy refill gap detection API endpoint as a separate monitor to ensure adherence alerts are being generated.
- Add the telemedicine and coordinator platform with a 2-minute interval; include a WebRTC connectivity test endpoint if the platform exposes one, in addition to the HTTPS dashboard check.
- Add the genetic counseling and family cascade screening coordination platform with a 2-minute interval; configure alerting to the genetics team lead in addition to the standard on-call rotation.
- Add the recurrent sinopulmonary infection and chronic lung disease monitoring platform with a 2-minute interval; include pulmonary function test result integration API as a secondary endpoint.
- Add the EHR integration endpoint with a 5-minute interval; configure body content checks verifying that the HL7 FHIR integration handshake returns a valid capability statement.
- Configure SSL certificate monitoring for all platform domains with alerting at 30, 14, and 7 days before expiration; enable the public status page and share its URL with the patient advocacy contact and all treating clinicians in the CFB deficiency program.
Conclusion
Complement Factor B Deficiency stands at the intersection of extreme immunological rarity and profound clinical vulnerability: with fewer than 20 cases in the published literature, each affected patient represents a unique management challenge that demands uninterrupted access to specialized complement function monitoring, broad-spectrum encapsulated bacterial infection surveillance targeting pneumococcus and Haemophilus influenzae as primary threats, comprehensive multi-valent vaccination coordination that goes well beyond standard complement deficiency protocols, lifelong prophylaxis adherence tracking, and genetic counseling workflows that extend care from the proband into the broader family network — all mediated through digital health platforms whose uptime is not a technical preference but a clinical safety requirement. The absence of C3bBb convertase in these patients eliminates the amplification loop that healthy individuals rely on for continuous antibody-independent bacterial surveillance, and no pharmacological intervention yet restores that function; the only tools available are vaccines, prophylactic antibiotics, and the vigilant surveillance that detects early infection before it becomes fatal sepsis, which means the platforms coordinating that surveillance must be monitored with the same intensity as the patients themselves. Vigilmon provides the complement care technology sector with the granular, tiered, multi-channel uptime monitoring infrastructure that translates clinical urgency into operational reliability — ensuring that when an AP50 result needs to reach a clinician, a sepsis alert needs to reach an on-call team, or a vaccination booster reminder needs to reach a family, the platform is available, the data flows, and the patient is protected.
External monitoring from Vigilmon provides the independent, infrastructure-agnostic uptime surveillance that ensures CFB Deficiency care platforms are never assumed to be available when they are not — delivering 1-minute check intervals, multi-region consensus alerting that eliminates false positives, SSL certificate expiry warnings 30 days in advance, automatic status pages that communicate platform state to all stakeholders in real time, and Slack and PagerDuty integrations that route each alert to the clinical team member best positioned to act on it.
Start monitoring your Complement Factor B Deficiency care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #ComplementFactorBDeficiency #CFBDeficiency #alternativePathway #C3convertase #C3bBb #encapsulatedBacteria #pneumococcal #HaemophilusInfluenzae #complementDeficiency #primaryImmunodeficiency #AP50 #CH50 #complementFunction #prophylacticAntibiotics #vaccinationTracking #rareDisease #immunologyMonitoring #sepsisAlert #PCV20 #PPSV23 #HibVaccine #meningococcalVaccine #geneticCounseling #autossomalRecessive #CFBgene #uptimeMonitoring #healthcareTech #vigilmon #complementCare #infectiousDiseaseMonitoring